SB
Senti Biosciences Holdings, Inc.
SEC filingBiotechnology · South San Francisco, CA
Amount raised$10Msold at filing
Total offering$40M$30M still open
Investors in the raise1count reported to the SEC
FiledJun 4, 2026first sale May 20, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Frances D. SchulzDirector
James J. CollinsDirector
Jay J. CrossExecutive Officer
Brenda D. CooperstoneDirector
Timothy LuExecutive Officer, Director
Bryan J. BaumDirector
Kanya J. RajangamExecutive Officer
Feng J. HsiungDirector
Donald D. TangDirector
Edward MathersDirector
Executive officers, directors and promoters as listed on the Form D.